The FDA Is Asking for Public Input on Ibogaine Trial Design. Comments Close Nov. 20.
On Oct. 5, the Food and Drug Administration asked for comment on how early-phase ibogaine trials should run, including a starting dose of no more than 10 mg/kg and inpatient cardiac monitoring. Comments are due Nov. 20. This is trial design, not an approval.
On Oct. 5, the Food and Drug Administration announced a request for information on how early-phase clinical trials of ibogaine should be designed. The notice, published in the Federal Register on Oct. 6, opens a public docket, and comments are due Nov. 20.
This is trial design, not an approval. The agency says the notice "does not establish legally enforceable requirements or regulatory expectations, nor does it represent FDA's final views." "With ibogaine, there are important scientific questions as well as serious safety concerns," Michael Davis, director of the FDA's Center for Drug Evaluation and Research, said in the agency's announcement.
What the FDA is considering
The FDA's preliminary design is a trial in which small groups each receive a single dose, with the dose rising from one group to the next. The starting dose would be justified by published literature and would not exceed 10 mg/kg. Participants could be dosed one at a time, and escalation could follow review by a safety review committee, a data and safety monitoring board and the FDA.
The care setting would be an inpatient unit equipped to manage a life-threatening arrhythmia: continuous rhythm monitoring, a physician-led team trained in advanced cardiac life support, a defibrillator at the bedside, drugs to treat torsades de pointes, emergency pacing and ventilator support. Monitoring would continue until there are no abnormal rhythms and the QTc has returned to near baseline, which could take as long as 36 hours. Participants could be genotyped for CYP2D6, with only fast and intermediate metabolizers enrolled.
In the draft, dosing would pause for review after a sustained ventricular arrhythmia or seizure, QTc prolongation above 500 ms lasting more than two days, new suicidal thoughts or behavior after the acute effects wear off, or a possibly related death or serious adverse event. Before dosing, participants would stop medications that prolong the QTc interval, slow the heart rate, interact with CYP2D6 or raise serotonin levels, including methadone and buprenorphine, antipsychotics and selective serotonin reuptake inhibitors.
Why the risks drive the design
The notice says ibogaine commonly causes substantial QTc prolongation, which has been associated with life-threatening ventricular arrhythmias and death. It also cites dose-dependent neurotoxicity in animal studies. In one prospective study of patients with opioid use disorder who received a single 10 mg/kg dose, all participants had severe transient ataxia.
The agency says doses of 5 to 20 mg/kg described in published clinical reports lack adequate safety margins based on nonclinical data, and that most studies lack participant-level data.
The notice sketches how the first trials might run. It does not signal that ibogaine is near the clinic, and every protocol element is open to comment until Nov. 20.
Where physician input is most useful
For addiction medicine, the FDA asks how best to discontinue opioid agonist medications before dosing, including setting, duration and ways to manage the loss of opioid tolerance. It says trials in opioid use disorder should have an addiction medicine physician on both oversight bodies.
For cardiology, the questions include whether an intensive care unit or hospital telemetry is the right setting, how to manage QTc prolongation from a single-dose drug, and whether a baseline QTcF of 430 ms or greater should exclude participants. The FDA wants a cardiologist on the safety review committee and on the monitoring board, which would also include a neurologist, a psychiatrist and a biostatistician.
For psychiatry, one possible population is adults with moderate to severe PTSD for at least six months that has not responded to an adequate SSRI course and a full course of PTSD-focused psychotherapy. The draft proposes cognitive testing through 12 months after dosing. The FDA says useful comments name the element, say whether to keep or change it, and supply the data or clinical experience behind that view. It is not seeking comment on scheduling, legalization or the merits of any specific product.
How the guidance and the executive order fit
On July 14, the FDA issued final guidance, Psychedelic Drugs: Considerations for Clinical Investigations, which the ibogaine notice builds on. Executive Order 14401, signed April 18, directs the FDA and the Drug Enforcement Administration to establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act. It also directs at least $50 million through the Advanced Research Projects Agency for Health to partner with states.
According to the notice, the Department of Health and Human Services is funding early-phase work through that agency and the National Institute on Drug Abuse, and is prioritizing adults with opioid use disorder and adults with PTSD. The FDA has also allowed an early-phase study of noribogaine, an ibogaine derivative, in alcohol use disorder to proceed.
What to do before Nov. 20
The notice runs seven pages in the Federal Register; sections II and III cover the design and the questions. Comments go to Docket FDA-2026-N-10429 on regulations.gov until 11:59 p.m. Eastern on Nov. 20, and late comments will not be considered. Physicians who want a more formal role in FDA review can also apply to its advisory committees.
Comments are public, so leave out any patient identifiers. The FDA also asks what individual-level pharmacokinetic, electrocardiographic and product information would make data from treatment outside the United States usable. Clinicians who have cared for patients after such treatment may hold some of it.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
